Abbott Laboratories Slides 0.36% on $780M Volume as Liquidity Ranks 144th Amid 44% Drop from Prior Day

Abbott Laboratories (ABT) closed at a 0.36% decline on October 2, 2025, with a trading volume of $780 million, reflecting a 44.01% drop from the previous day’s activity. The stock ranked 144th in terms of market liquidity amid mixed sectoral performance.

Analysts noted limited catalysts for the stock’s movement, as recent earnings reports and product pipeline updates remained unchanged from prior quarters. While no major regulatory or partnership announcements were disclosed, the company’s focus on expanding its diagnostic solutions portfolio continues to shape investor sentiment. Market participants observed that the reduced trading volume may signal temporary profit-taking following recent gains in the healthcare sector.

To run this cross-section, daily-rebalanced portfolio back-test properly I need to pin down a few details that aren’t fully specified yet: 1. Universe—Which market’s stocks should be considered when ranking by volume? • All U.S. common stocks (≈6,000 tickers)—default, or • An index constituent set (e.g., Russell 3000, S&P 1500, etc.). 2. Weighting—Equal-weight each of the 500 names you buy each day (default) or volume-weighted / market-cap-weighted? 3. Rebalancing & holding period—Confirm you want to: • Form the portfolio at each day’s close, • Hold the basket for exactly one trading day, • Close all positions at the next day’s close, then form a new basket. 4. Costs—Include any transaction cost assumptions (e.g., 5 bp per leg), or ignore them? 5. Benchmark / output—Any particular benchmark you’d like the returns compared to (e.g., SPY), or just stand-alone performance stats? Once these points are clarified, I’ll construct the data-retrieval and back-testing steps.